R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
- Authors
- 이홍기[이홍기]; 최윤석[최윤석]; 김양수[김양수]; 이호섭[이호섭]; 김석진[김석진]; 박병배[박병배]; 박성규[박성규]; 정준원[정준원]; 김성용[김성용]; 김인호[김인호]; 김여경[김여경]; 김정아[김정아]; 박지니[박지니]; 엄현석[엄현석]; 박건우[박건우]; 심혁[심혁]; 이정림[이정림]
- Issue Date
- 2014
- Publisher
- 대한혈액학회
- Keywords
- Diffuse large B-cell lymphoma; Hematopoietic stem cell transplantation; Autologous transplantation; Rituximab; Survival analysis
- Citation
- Blood Research, v.49, no.2, pp.107 - 114
- Indexed
- SCOPUS
KCI
- Journal Title
- Blood Research
- Volume
- 49
- Number
- 2
- Start Page
- 107
- End Page
- 114
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/55375
- ISSN
- 2287-979X
- Abstract
- Background We investigated factors that influence outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT).
Methods We retrospectively evaluated survival differences between subgroups based on the age-adjusted International Prognostic Index (aaIPI) and revised-IPI (R-IPI) at diagnosis, disease status, and positron emission tomographic/computerized tomographic (PET/CT) status at transplantation in 51 CD20-positive DLBCL patients treated with R-CHOP followed by upfront Auto-SCT.
Results Patients had either stage I/II bulky disease (5.9%) or stage III/IV disease (94.1%). The median patient age at diagnosis was 47 years (range, 22‒66 years); 53.3% and 26.7% had high-intermediate and high risks according to aaIPI, respectively. At the time of Auto-SCT, 72.5% and 27.5% experienced complete (CR) and partial remission (PR) after R-CHOP, respectively. The median time from diagnosis to Auto-SCT was 7.27 months (range, 3.4‒ 13.4 months). The 5-year overall (OS) and progression-free survival (PFS) were 77.3% and 72.4%, respectively. The 5-year OS and PFS rates according to aaIPI, R-IPI, and PET/CT status did not differ between the subgroups. More importantly, the 5-year OS and PFS rates of the patients who achieved PR at the time of Auto-SCT were not inferior to those of the patients who achieved CR (P=0.223 and 0.292, respectively).
Conclusion Survival was not influenced by the aaIPI and R-IPI at diagnosis, disease status, or PET/CT status at transplantation, suggesting that upfront Auto-SCT might overcome unfavorable outcomes attributed to PR after induction chemoimmunotherapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.